The American Council of Cannabis Medicine has been quietly working behind the scenes to prepare for a future where cannabis is recognized as legitimate medicine—and reimbursable through health insurance.
The organization currently holds nine seats on a special committee convened by the Health Secretary’s office. They have been tasked with advising President Trump on cannabis efficacy during the research phase tied to the executive order on rescheduling.
Beyond having a front-row seat in shaping federal cannabis policy, the Council is also building the infrastructure to integrate medical cannabis into the U.S. healthcare insurance system.
Today, my guest is Mathew Rothman, Chief Science and Marketing Officer at Cannalnx—the exclusive technology partner to the American Council of Cannabis Medicine, making this integration possible. This month, they’re rolling out a new program through licensed insurance brokers that allows patients to receive monthly reimbursements—typically between $100 and $175—for medical cannabis and related physician visits.